TOPLINE:

Patients with systemic lupus erythematosus (SLE) had an approximately twofold increased risk for mortality compared with matched control individuals. They also had an increased risk for various complications, such as myocarditis/pericarditis and fibromyalgia. Black patients had a higher risk for death than White patients.

METHODOLOGY:

• Researchers conducted a retrospective observational study in England, using data from the Clinical Practice Research Datalink.
• A total of 4937 adults with new diagnoses of SLE (median age at diagnosis, 47 years; 87.9% women; 71.1% White) between 2012 and 2023, along with 19,707 control individuals matched by age, sex, and primary care practice, were included.
• Data on demographics, including self-reported ethnicity, and comorbidities were collected.
• The outcomes of interest included all-cause mortality and the following complications: ischaemic heart disease, heart failure, stroke and transient ischaemic attack, thrombosis, myocarditis and/or pericarditis, diabetes, chronic kidney disease (CKD), interstitial lung disease (ILD), osteoporosis, fractures, solid cancers, and fibromyalgia.
• Mortality risk was estimated using flexible parametric survival models (Royston-Parmar) and compared between patients with SLE and control individuals.

TAKEAWAY:

• Patients with SLE had approximately double the mortality risk compared with matched control individuals (adjusted hazard ratio [aHR], 2.06; 95% CI, 1.84-2.32).
• Black patients with SLE had a higher risk for death over the study period than White patients (aHR, 1.64; 95% CI, 1.05-2.55), with the greatest excess mortality risk in the first year after diagnosis (aHR, 2.21; 95% CI, 1.04-4.72).
• Patients with SLE had elevated risks for all the studied complications except solid cancers, with the highest risk estimates for myocarditis/pericarditis (aHR, 10.72; 95% CI, 6.76-17.01), ILD (aHR, 9.77; 95% CI, 6.65-14.34), CKD stage 5 (aHR, 7.65; 95% CI, 4.75-12.34), and fibromyalgia (aHR, 7.57; 95% CI, 6.13-9.34).
• Among patients with SLE, Black ethnicity was associated with higher risks for diabetes (aHR, 2.55; 95% CI, 1.73-3.76), thrombosis (aHR, 2.10; 95% CI, 1.24-3.55), myocarditis/pericarditis (aHR, 4.99; 95% CI, 2.97-8.39), and ILD (aHR, 3.14; 95% CI, 1.81-5.47) than White ethnicity.

IN PRACTICE:

"While SLE outcomes are universally poor, our findings suggest the presence of ethnicity-based inequalities in both complications and mortality that require urgent attention," the authors of the study wrote, further adding that "[The study] findings raise concern that ethnicity-based inequities in outcomes may limit the benefits of modern SLE therapies in real-world practice."

SOURCE:

The study was led by Samir Patel, King's College London, London, England. It was published online on April 17, 2026, in Rheumatology.

LIMITATIONS:

The study relied on electronic health records, where the accuracy of coding during consultations may have changed over time due to evolving practice and data capture methods. Although primary care physicians typically assign SLE codes only after specialist review, the possibility of diagnostic misclassification cannot be entirely excluded. Data on certain SLE-specific complications, such as lupus nephritis, could not be captured, and cause-specific deaths could not be determined. Relative underreporting of complications may have existed among control individuals.

DISCLOSURES:

No specific funding was received for this study. Three authors disclosed receiving honoraria, grant funding, advisory board fees, and/or support for attending educational meetings from multiple pharmaceutical companies, one of whom also disclosed serving as a co-editor of Rheumatology and another reported being on its editorial board. Additionally, another author reported providing statistical reviews for Rheumatology.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.